Considering this limitation, single-agent immunotherapy is still the best available option for previously untreated patients with metastatic NSCLC with a tumor proportional score (TPS) of PDL-1 ≥ 50% and without EGFR, ALK, and ROS1 mutation [13]. This evidence concerns the gene CD274 and neoplasm.